75 Percent Of Drug Companies Formally Manage Investigator-Initiated Trials
Main Category: Pharma Industry / Biotech IndustryArticle Date: 04 Mar 2010 - 3:00 PDT
Investigator-initiated trials (IITs) provide companies with clinical data to expand scientific understanding of their drugs and reap a number of additional benefits. IIT management, however, can be challenging.
Data collected by business intelligence firm Cutting Edge Information show that 75% of surveyed companies have some form of dedicated IIT management group in place. Such teams accelerate IIT processing and help in long-term trial oversight.
"To translate strategic goals into a concrete plan of action, many companies have developed standard operating procedures for collecting, screening, and approving IIT proposals," said Jason Richardson, president of Cutting Edge Information. "IIT management teams save time, reduce confusion during the evaluation and approval process, and ensure that each study proposal receives a fair appraisal."
Companies have taken further steps to ensure tangible results from IITs -- and to find a range of uses for their results. To accomplish this goal, they have adopted hands-on IIT philosophies and increased oversight during trials.
"Even with standardized processes in place, the proposal-evaluation process can take a while," said Eric Bolesh, research director at Cutting Edge Information. "Rather than using a high-level committee to formally evaluate proposals -- only to reject them or find information missing -- IIT teams quickly identify proposals that are lacking necessary information or that are obviously bad fits for the company."
A key step in improving ongoing study management is managing investigators' expectations while clarifying their roles and responsibilities. This process begins even before a trial starts, as IIT groups quickly respond to trial proposals. During a study, some investigators expect to be left alone to run their studies, whereas others prefer regular contact, so IIT groups customize their approaches based on each investigator's needs and expectations.
While surveying teams who handle their companies' IIT processes, Cutting Edge Information (http://www.cuttingedgeinfo.com/) identified the following key principles for success:
- Define IIT proposal protocols
- Quickly eliminate undesirable proposals
- Build dedicated IIT groups and budgets
- Take a proactive approach to attracting, managing and using IITs
- Manage investigators' expectations and clarify roles and responsibilities
For more inquiries about Cutting Edge Information's Clinical Development collection, visit here.
Source
Cutting Edge Information
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/181135.php>
APA
http://www.medicalnewstoday.com/releases/181135.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Good Direction - 75 Percent Of Drug Companies Formally Manage Investigator-Initiated Trials
posted by Allan Ono on 4 Mar 2010 at 3:09 pmMaking the most of drugs that have already been approved by the FDA seems like a good way to expand treatment options without the hyperbole about clinical trials vs. me-too drugs. The Phase IV / IIT studies should be happening a lot more so we can find more ways to effectively use drugs that have already proven safe.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



